Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Brady

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Annals of Surgical Oncology|May 3, 2012
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremityG M Beasley, A P Coleman, A Raymond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patientsG D Shah, N D Socci, J S Gold, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 13, 2004
Estimating the relative risk of developing melanoma in INK4A carriersM Berwick, I Orlow, S Mahabir, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Annals of Surgical Oncology|May 3, 2012
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremityG M Beasley, A P Coleman, A Raymond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patientsG D Shah, N D Socci, J S Gold, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 13, 2004
Estimating the relative risk of developing melanoma in INK4A carriersM Berwick, I Orlow, S Mahabir, et al.
Pageof 7